SLC-0111

Term ID

CHEBI:232342

Synonyms

1-(4-fluorophenyl)-3-(4-sulfamoylphenyl)urea
4-(4-fluorophenylureido)-benzenesulfonamide
4-[3-(4-fluorophenyl)ureido]benzenesulfonamide
4-{[(4-fluorophenyl)carbamoyl]amino}benzene-1-sulfonamide
4-{[(4-fluorophenyl)carbamoyl]amino}benzenesulfonamide
MST-104
NSC-213841
SLC 0111
SLC0111
U 104
U-104
U104
WBI-5111

Definition

It is a potent carbonic anhydrase inhibitor (Ki = 45.1 nM and 4.5 nM for CA IX and CA XII, respectively) that is in clinical trials for the treatment of hypoxic malignancies .

References

cas:178606-66-1
drugbank:DB18815
pdb-ccd:WWZ
pmc:PMC5693064
pubmed:20922253
pubmed:26810836
pubmed:28347633
pubmed:28363153
pubmed:28947945
pubmed:29263302
pubmed:29962205
pubmed:30362384
pubmed:30445264
pubmed:30471577
pubmed:30978604
pubmed:32251122
pubmed:32396749
pubmed:32738591
pubmed:33667848
pubmed:33773285
pubmed:34221901
pubmed:34232641
pubmed:34871842
pubmed:34894950
pubmed:35328549
pubmed:35365193
pubmed:36146927
pubmed:36776327
pubmed:36982873
pubmed:37321108
pubmed:37501287
pubmed:37549770
pubmed:38713910
pubmed:39316272

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from SLC-0111

Phenotype where environments contain SLC-0111

Phenotype modified by environments containing SLC-0111

Phenotype affecting SLC-0111

Human Disease Model